Overview

The SIM-SOF Trial for Hepatitis C

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

Randomized trial of Hepatitis C-genotype 1-infected patients with compensated cirrhosis comparing the standard of care (Peginterferon/Ribavirin/Sofosbuvir) versus the off-label combination of simeprevir+ sofosbuvir without Ribavirin.

Phase:

Phase 4

Details

Lead Sponsor:

Center For Hepatitis C, Atlanta, GA

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b
Ribavirin
Simeprevir
Sofosbuvir